Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CencoraWBO:ABC +0.19%70 3-Year Share Buyback Ratio is 2.00 as of Mar. 2026, which is 33% above its 10-year median of 1.50. GuruFocus rates WBO:ABC with a GF Score™ of 70/100 and a GF Value™ of €257.66 (Fairly Valued). The stock has 1 warning sign investors should review. Among 67 Medical Distribution companies, Cencora ranks better than 83.58% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cencora's current 3-Year Share Buyback Ratio was 2.00%.
The historical rank and industry rank for Cencora's 3-Year Share Buyback Ratio or its related term are showing as below:
WBO:ABC'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -24 Med: 1.5 Max: 9.9
Current: 2
During the past 13 years, Cencora's highest 3-Year Share Buyback Ratio was 9.90%. The lowest was -24.00%. And the median was 1.50%.
WBO:ABC's 3-Year Share Buyback Ratio is ranked better than 83.58% of 67
companies
in the Medical Distribution industry
Industry Median: -0.5
vs WBO:ABC: 2.00
Cencora (WBO:ABC) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cencora 3-Year Share Buyback Ratio Related Terms
WBO:ABC vs CAH, MCK, HSIC: 3-Year Share Buyback Ratio Comparison
For the Medical Distribution subindustry, Cencora's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora 3-Year Share Buyback Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cencora's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 2.00 mean?
Cencora (WBO:ABC) has a 3-Year Share Buyback Ratio of 2.00 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cencora and its competitors. This is 33% above median its historical median of 1.50. According to the industry distribution chart, Cencora ranks #11 out of 67 companies in the Medical Distribution industry, placing it in the top 16.4%.
Is Cencora's 3-Year Share Buyback Ratio too high?
Cencora's current 3-Year Share Buyback Ratio of 2.00 is 33% above median its 10-year median of 1.50. Based on the distribution chart, Cencora ranks #11 out of 67 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cencora has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's 3-Year Share Buyback Ratio compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #11 out of 67 companies for 3-Year Share Buyback Ratio. This places Cencora in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Distribution company?
A good 3-Year Share Buyback Ratio depends on the Medical Distribution industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cencora and its competitors. Cencora's current 3-Year Share Buyback Ratio is 2.00, which is 33% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €257.66, compared to a current price of €270.70 — trading 5.1% above its estimated fair value. The current 3-Year Share Buyback Ratio is 2.00, which is 33% above median its 10-year median of 1.50. Cencora's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cencora (WBO:ABC), the current 3-Year Share Buyback Ratio is 2.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €270.70 is trading 5.1% above its estimated GF Value™ of €257.66.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
3-Year Share Buyback Ratio: 2.00 (33% above median its 10-year median of 1.50)
GF Value™: €257.66 vs. price of €270.70 (5.1% above fair value)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
70GF Score
Get the complete analysis for WBO:ABC
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
